Management maintains a conservative liquidity position with a reported cash balance of $547,498, though the absence of formal cash flow statements prevents verification of actual earnings conversion.
| Metric | Oct'24 | Oct'23 | Oct'22 | Oct'21 |
|---|
| Cash from Operations | 960.47K | 126.54K | 1.44M | -497.86K |
| Operating CF Margin % | 40.32% | 5.15% | 75.14% | -53.47% |
| Operating CF Growth % | 659.04% | -91.23% | 389.7% | - |
| Net Income | 478.56K | 852.04K | 191.3K | -484.96K |
| Depreciation & Amortization | 22.69K | 20.06K | 30.49K | 39.01K |
| Stock-Based Compensation | 0 | 0 | 0 | 0 |
| Deferred Taxes | -21.46K | -33.74K | -1.29K | 0 |
| Other Non-Cash Items | 226.28K | 199.24K | 48.04K | 1.66K |
| Working Capital Changes | 254.41K | -911.07K | 1.17M | -53.57K |
| Change in Receivables | -135.6K | -603.5K | -143.85K | -46.67K |
| Change in Inventory | 10.47K | -2.82K | 193.58K | -19.23K |
| Change in Payables | -176.13K | 69.43K | 56.81K | 44.83K |
| Cash from Investing | -508.14K | 1.02M | -1.55M | -12.91K |
| Capital Expenditures | -85.57K | -22.68K | -11.89K | -12.91K |
| CapEx % of Revenue | 3.59% | 0.92% | 0.62% | 1.39% |
| Acquisitions | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - |
| Other Investing | -422.57K | 1.05M | -1.54M | 0 |
| Cash from Financing | -957.39K | -676.92K | 669.65K | 498.63K |
| Debt Issued (Net) | -69.14K | -715.19K | 135.5K | 235.56K |
| Equity Issued (Net) | 500 | 38.27K | 534.15K | 263.07K |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 |
| Other Financing | -888.75K | 0 | 0 | 0 |
| Net Change in Cash | -486.14K | 458.92K | 502.02K | -8.44K |
| Free Cash Flow | 874.9K | 103.86K | 1.43M | -510.76K |
| FCF Margin % | 36.73% | 4.22% | 74.52% | -54.86% |
| FCF Growth % | 742.38% | -92.74% | 380.05% | - |
| FCF per Share | 0.03 | 0.00 | 0.05 | -0.02 |
| FCF Conversion (FCF/Net Income) | 2.01x | 0.15x | 7.54x | 1.03x |
| Interest Paid | 0 | 0 | 194 | 1.19K |
| Taxes Paid | 0 | 0 | 0 | 0 |
Geopolitical and Regulatory Exposure
Given the absence of reported cash flow statements, the relationship between the company's 20.09% net margin and actual cash generation remains entirely opaque, preventing a definitive assessment of whether reported earnings are supported by tangible cash inflows or are instead inflated by non-cash accounting accruals.
Investors should exercise caution as the lack of cash flow data makes it impossible to determine if the high net income is being converted into liquidity. Without visibility into the gap between net income and operating cash flow, the sustainability of the company's reported profitability remains a significant analytical uncertainty.
Based on the company's reported cash balance of $547,498, it appears that management is maintaining a conservative liquidity position, yet the lack of disclosed cash flow statements obscures how this capital is being deployed or whether it is effectively accessible given the firm's Chinese operational structure.
The company's minimal debt-to-equity ratio suggests a focus on balance sheet preservation rather than aggressive capital deployment. However, without insight into cash usage, it is unclear if this cash is being held for strategic reinvestment or if it is trapped by regulatory capital controls in the PRC.
As noted in recent financial disclosures, the absence of a cash flow statement prevents analysts from identifying potential off-balance sheet liabilities or capitalized costs that could be masking the true economic cost of maintaining the Park Ha brand's localized franchise-based distribution network within the Chinese market.
The high gross margin of 91.80% may be misleading if significant costs are being capitalized rather than expensed, which would artificially inflate both net income and operating cash flow. Further investigation is required to determine if the company's reported financial health is truly reflective of its underlying cash-generating capacity.
Quick answers to the most common questions about buying BYAH stock.
Park Ha Biological Technology Co., Ltd. Ordinary Shares (BYAH) generated $1.0M in net cash from operating activities in 2024. This reflects the cash generated directly from core business operations.
Park Ha Biological Technology Co., Ltd. Ordinary Shares (BYAH) generated $0.9M in free cash flow in 2024. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Park Ha Biological Technology Co., Ltd. Ordinary Shares (BYAH) spent $0.1M on capital expenditures in 2024. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.